Cargando…
Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation
BACKGROUND: Polycystic ovarian syndrome (PCOS) is characterized by increased ovarian angiogenesis and vascularity. Accumulating evidence indicates that vascular endothelial growth factor (VEGF) is increased in PCOS and may play an important role in these vascular changes and the pathogenesis of this...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150963/ https://www.ncbi.nlm.nih.gov/pubmed/25141961 http://dx.doi.org/10.1186/1477-7827-12-82 |
_version_ | 1782332974293843968 |
---|---|
author | Tal, Reshef Seifer, David B Grazi, Richard V Malter, Henry E |
author_facet | Tal, Reshef Seifer, David B Grazi, Richard V Malter, Henry E |
author_sort | Tal, Reshef |
collection | PubMed |
description | BACKGROUND: Polycystic ovarian syndrome (PCOS) is characterized by increased ovarian angiogenesis and vascularity. Accumulating evidence indicates that vascular endothelial growth factor (VEGF) is increased in PCOS and may play an important role in these vascular changes and the pathogenesis of this disease. Placental growth factor (PlGF), a VEGF family member, has not been previously characterized in PCOS women. We investigated levels and temporal expression patterns of PlGF and its soluble receptor sFlt-1 (soluble Fms-like tyrosine kinase) in serum and follicular fluid (FF) of women with PCOS during controlled ovarian stimulation. METHODS: This was a prospective cohort study of 14 PCOS women (Rotterdam criteria) and 14 matched controls undergoing controlled ovarian stimulation. Serum was collected on day 3, day of hCG and day of oocyte retrieval. FF was collected on retrieval day. PlGF, sFlt-1 and anti-mullerian hormone (AMH) protein concentrations were measured using ELISA. Since sFlt-1 binds free PlGF, preventing its signal transduction, we calculated PlGF bioavailability as PlGF/sFlt-1 ratio. RESULTS: Serum PlGF and sFlt-1 levels were constant throughout controlled ovarian stimulation, and no significant differences were observed in either factor in PCOS women compared with non-PCOS controls at all three measured time points. However, FF PlGF levels were increased 1.5-fold in PCOS women compared with controls (p < 0.01). Moreover, FF PlGF correlated positively with number of oocytes retrieved and the ovarian reserve marker anti-mullerian hormone (AMH) and negatively with age. In addition, FF sFlt-1 levels were decreased 1.4-fold in PCOS women compared to controls (p = 0.04). PlGF bioavailability in FF was significantly greater (2-fold) in PCOS women compared with non-PCOS controls (p < 0.01). CONCLUSIONS: These data provide evidence that FF PlGF correlates with ovarian stimulation and that its bioavailability is increased in women with PCOS undergoing controlled ovarian stimulation. This suggests that PlGF may play a role in PCOS pathogenesis and its angiogenic dysregulation. |
format | Online Article Text |
id | pubmed-4150963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41509632014-09-03 Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation Tal, Reshef Seifer, David B Grazi, Richard V Malter, Henry E Reprod Biol Endocrinol Research BACKGROUND: Polycystic ovarian syndrome (PCOS) is characterized by increased ovarian angiogenesis and vascularity. Accumulating evidence indicates that vascular endothelial growth factor (VEGF) is increased in PCOS and may play an important role in these vascular changes and the pathogenesis of this disease. Placental growth factor (PlGF), a VEGF family member, has not been previously characterized in PCOS women. We investigated levels and temporal expression patterns of PlGF and its soluble receptor sFlt-1 (soluble Fms-like tyrosine kinase) in serum and follicular fluid (FF) of women with PCOS during controlled ovarian stimulation. METHODS: This was a prospective cohort study of 14 PCOS women (Rotterdam criteria) and 14 matched controls undergoing controlled ovarian stimulation. Serum was collected on day 3, day of hCG and day of oocyte retrieval. FF was collected on retrieval day. PlGF, sFlt-1 and anti-mullerian hormone (AMH) protein concentrations were measured using ELISA. Since sFlt-1 binds free PlGF, preventing its signal transduction, we calculated PlGF bioavailability as PlGF/sFlt-1 ratio. RESULTS: Serum PlGF and sFlt-1 levels were constant throughout controlled ovarian stimulation, and no significant differences were observed in either factor in PCOS women compared with non-PCOS controls at all three measured time points. However, FF PlGF levels were increased 1.5-fold in PCOS women compared with controls (p < 0.01). Moreover, FF PlGF correlated positively with number of oocytes retrieved and the ovarian reserve marker anti-mullerian hormone (AMH) and negatively with age. In addition, FF sFlt-1 levels were decreased 1.4-fold in PCOS women compared to controls (p = 0.04). PlGF bioavailability in FF was significantly greater (2-fold) in PCOS women compared with non-PCOS controls (p < 0.01). CONCLUSIONS: These data provide evidence that FF PlGF correlates with ovarian stimulation and that its bioavailability is increased in women with PCOS undergoing controlled ovarian stimulation. This suggests that PlGF may play a role in PCOS pathogenesis and its angiogenic dysregulation. BioMed Central 2014-08-20 /pmc/articles/PMC4150963/ /pubmed/25141961 http://dx.doi.org/10.1186/1477-7827-12-82 Text en © Tal et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Tal, Reshef Seifer, David B Grazi, Richard V Malter, Henry E Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation |
title | Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation |
title_full | Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation |
title_fullStr | Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation |
title_full_unstemmed | Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation |
title_short | Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation |
title_sort | follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150963/ https://www.ncbi.nlm.nih.gov/pubmed/25141961 http://dx.doi.org/10.1186/1477-7827-12-82 |
work_keys_str_mv | AT talreshef follicularfluidplacentalgrowthfactorisincreasedinpolycysticovariansyndromecorrelationwithovarianstimulation AT seiferdavidb follicularfluidplacentalgrowthfactorisincreasedinpolycysticovariansyndromecorrelationwithovarianstimulation AT grazirichardv follicularfluidplacentalgrowthfactorisincreasedinpolycysticovariansyndromecorrelationwithovarianstimulation AT malterhenrye follicularfluidplacentalgrowthfactorisincreasedinpolycysticovariansyndromecorrelationwithovarianstimulation |